- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248194
Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding (TEA)
Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding
Abnormal uterine bleeding (AUB) is any alteration in the pattern or volume of menstrual blood flow and heavy menstrual bleeding affects up to 30% of women at some time during their reproductive years. Abnormal menstruation can be due to conditions such as pregnancy complication uterine fibroids and adenomyosis, but in a large proportion of cases, the etiology is unclear, a condition generally referred to as dysfunctional uterine bleeding (DUB). Treatment options for DUB include symptomatic medical treatment or surgery, traditionally hysterectomy.
Hysteroscopically guided endometrial ablation methods have been shown to be effective and safe alternatives to hysterectomy for management of DUB. These methods require particular skills and experience and a long learning curve to be performed effectively and safely.
Through the past three decades DUB patients in Assiut university hospital were treated with either electrosurgical ablation or hysterectomy. When faced with hysteroscopic challenges during transcervical resection of the endometrium or rollerball coagulation, we used to shift to thermal balloon as backup method . However, expensive uterine balloon could not infrequently be afforded because of financial constrains and limited health resources . Therefore, another method was used as backup for hysteroscopic failures. It was first tried via insulating the conventional double-ended uterine curette then through a specially designed tactile electrosurgical ablation (TEA) probe.The technique of TEA is largely similar to the dilatation and curettage procedure both principally and practically. Hence, the basic requirements for its performance are the general awareness with electrosurgical principles and adequate experience in performing dilatation and curettage. TEA is done by specially designed tactile diathermy probe that carried the job of electrosurgical ablation without hysteroscopy or distension media first in an experimental session that clearly clarified the reproducibility of the depth of thermal damage and safety of the tactile electrosurgical ablator . Thereafter, TEA was successfully performed with satisfactory short and medium term outcomes for ten cases with DUB during an active, relentless bleeding attack. TEA is done under laparoscopic monitoring.
The aim of the present work is to present TEA as a simple, inexpensive, novel backup approach for treatment of DUB.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt
- Woman's Health Hospital-Assiut University.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with dysfunctional uterine bleeding aged between 40 to 50 years
- Unsuccessful medical treatment.
- No intrauterine abnormalities.
- Endometrial biopsy negative for atypia and cancer.
- follicle stimulating hormone level not exceeds 30 mills-International unit
- Family complete
- Patients who are not candidate for hysterectomy because of medical or surgical risks.
Exclusion Criteria:
- Coexisting gynecological pathology (e.g. uterovaginal prolapsed, ovarian pathology, pelvic inflammatory disease, cervical atypia).
- Endometrial hyperplasia with atypia and cancer..
- History or evidence of malignancy.
- Hyperplasia in the endometrial biopsy.
- Uterine size more than 12 weeks in size.
- Women with caesarean or myomectomy scar
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1"Tactile electrosurgical ablation"
Endometrial ablation will be done by Tactile electrosurgical ablation probe.
|
Other Names:
|
Active Comparator: Group 2 "Hysteroscopic endometrial ablation"
Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Satisfaction with the treatment at 12 month follow up
Time Frame: 12 moth
|
Satisfaction with the treatment will be measured at 1 year post procedure on 3-point scale-very satisfied, satisfied, and not satisfied.
|
12 moth
|
Change in menstrual status.
Time Frame: At 3, 6, 9, and12 months pot operatve.
|
Menstrual status will be reported as
|
At 3, 6, 9, and12 months pot operatve.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of treatment
Time Frame: 4 weeks
|
Acceptability of the procedure will be assessed in 3- point scale as cure or acceptable improvement in symptoms, treatment acceptable and would recommend treatment to others or not acceptable
|
4 weeks
|
Changes in health related quality of life
Time Frame: At 3, 6, 9, and 12 months post operative.
|
Health-related quality of life parameters will be completed using
|
At 3, 6, 9, and 12 months post operative.
|
Difference in operative time between the two groups in minutes.
Time Frame: 0-60 minutes
|
Difference in operative time is calculated using a stop watch.The zero minute is the time of starting the procedure.
The stop watch is on at the zero minute then sopped at the end of the procedure.time of anesthesia is not included.
|
0-60 minutes
|
Reporting of any intro-operative complications.
Time Frame: 0-60 minutes.
|
Intro-operative complications includes
|
0-60 minutes.
|
Reporting of any technical complications.
Time Frame: 0-60 minutes
|
Technical complications for transcervical resection of the endometrium (TCRE) includes
Technical complications for tactile electrosurgical ablation (TEA) includes
|
0-60 minutes
|
Difference in post-operative pain score using visual analogue scale between the two groups.
Time Frame: 4 hours.
|
Difference in post-operative pain score using visual analogue scale from 1-10.
|
4 hours.
|
Time needed for post operative recovery (days) of pain, vaginal bleeding, vaginal discharge, till full recovery and till return to work.
Time Frame: 28 days post operative
|
28 days post operative
|
|
Length of hospital stay in days
Time Frame: up to 2 days
|
Length of hospital stay in days is calculated from the day of operation till day of discharge.
|
up to 2 days
|
Difference in the cost of the two surgical procedure.
Time Frame: up to one hour.
|
Direct cost of the surgical procedure itself is calculated.The cost of the TCRE procedure will include the cost paid for the hysteroscopic unit and the cost of glycine used as distension media.The cost of the TEA procedure will include the cost of laparoscopy, the cost of TEA probe, and the cost of diagnostic hysteroscopy.
The cost of the investigations, anesthesia, pre and post operative treatments will be excluded from analysis as they are the same for both groups.
|
up to one hour.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Tactile ablation
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dysfunction Uterine Bleeding
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
-
University of California, DavisWashington University School of MedicineTerminatedUterine Bleeding Heavy | Abnormal Uterine Bleeding, UnspecifiedUnited States
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedAbnormal Uterine Bleeding
-
Chulalongkorn UniversityUnknown
-
Ain Shams Maternity HospitalCompletedDysfunctional Uterine BleedingEgypt
-
Indiana UniversityCompleted
-
Mansoura University HospitalUnknownDysfunctional Uterine Bleeding
-
Peptigroupe Inc.CompletedDysfunctional Uterine BleedingUkraine
-
BayerCompletedMetrorrhagiaUnited States, Canada
-
Cairo UniversityUnknownDysfunctional Uterine Bleeding
Clinical Trials on Hysteroscopic endometrial ablation
-
Università degli Studi dell'InsubriaCompletedPost-Menopausal Bleeding | Post-Menopausal Endometrial ThicknessItaly
-
Ullevaal University HospitalCompletedEndometrial Cancer | Endometrial PolypNorway
-
Birmingham Women's NHS Foundation TrustUnknown
-
Shu-Qin ChenUnknownQuality of Life | Sexual ActivityChina
-
Agency for Healthcare Research and Quality (AHRQ)CompletedMenorrhagia | Uterine Bleeding
-
Hologic, Inc.Unknown
-
Minerva Surgical, Inc.CompletedMenorrhagiaUnited States, Canada, Mexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesMexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesCanada
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesHungary